Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. April 2025 08:00 ET | Quelle: NephroDI Therapeutics

NephroDI Therapeutics’ Founder and CMO Jeff M. Sands, M.D. Receives the 2025 Robert W. Berliner Award for Excellence in Renal Physiology

April 25, 2025, Seattle, WA – NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on kidney disorders, announces that its Founder and CMO, Jeff M. Sands, M.D., is the recipient of the...
20. Juni 2024 07:00 ET | Quelle: NephroDI Therapeutics

NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney Disease

New funding to take NDI-5001 into and through clinical proof of concept in Congenital Nephrogenic Diabetes Insipidus (NDI)New investment complements previously announced strategic corporate...